ETHTAZ-4.5GM

4.5GM IV INJECTION

ETHTAZ-4.5GM is a combination antibiotic formulation comprising Piperacillin (4gm) and Tazobactam (0.5gm) for injection. This medication is used to treat a variety of bacterial infections by inhibiting bacterial growth and enhancing the efficacy of the antibiotic. The inclusion of Tazobactam protects Piperacillin from being broken down by beta-lactamase enzymes produced by bacteria, making it effective against resistant strains.

Common side effects may include:

• Nausea or vomiting

• Diarrhea

• Rash or itching

• Headache

• Fever

Severe side effects (rare):

• Allergic reactions (e.g., swelling, difficulty breathing)

• Severe diarrhea (indicative of Clostridioides difficile infection)

• Abnormal liver function tests

• Neutropenia (low white blood cell count)

• Administered via intravenous injection.

• Typically given in a hospital setting under medical supervision.

• The duration and dosage depend on the severity and type of infection.

• Regular monitoring of renal and liver function is advised, especially for prolonged usage.

• Risk of superinfection with prolonged use or misuse.

• Known allergy to Piperacillin, Tazobactam, or other beta-lactam antibiotics (e.g., penicillins, cephalosporins).

• Patients with a history of severe allergic reactions (e.g., anaphylaxis) to antibiotics.

• Hypersensitivity Reactions:

  • Always perform a skin test or allergy assessment before administration.

• Renal Impairment:

  • Dose adjustment is required for patients with kidney dysfunction.

• Pregnancy and Lactation:

  • Use during pregnancy only if clearly needed.

  • Caution is advised if used while breastfeeding.

• Interactions with Medications:

  • May interact with aminoglycosides, anticoagulants, or methotrexate, potentially altering their effects.

• Adults: 4.5gm every 6-8 hours, depending on the infection severity.

• Renal Impairment: Adjust dose based on creatinine clearance levels.

• Administer over 30 minutes via intravenous infusion.

• Aminoglycosides: Increased nephrotoxicity risk when co-administered.

• Anticoagulants (e.g., warfarin): Enhanced anticoagulant effect, increasing bleeding risk.

• Probenecid: Prolongs Piperacillin and Tazobactam serum levels.

• Administer ETHTAZ-4.5GM under strict medical supervision.

• Ensure proper hydration to avoid renal toxicity.

• Complete the full course of therapy even if symptoms improve to prevent antibiotic resistance.

• Dispose of unused medication as per local medical waste guidelines.

• Storage: Store in a cool, dry place at 20°C to 25°C (68°F to 77°F). Protect from light and moisture.

• Packaging: Available as a single-dose vial for intravenous administration.

• Formulation: Sterile powder for reconstitution.

• Clinical guidelines for Piperacillin-Tazobactam use in bacterial infections (2023).

• Product monograph: Piperacillin and Tazobactam for Injection USP, latest edition.

• CDC Guidelines on the treatment of multi-drug resistant bacterial infections (2023).

• WHO Essential Medicines List: Beta-lactam/beta-lactamase inhibitor combinations.